Calyon rebuilds Asian equity derivatives team

The hires include a new Taiwan sales head, who is expected to come on board in mid-December to replace Henry Hui, who left in mid-2007 for Citi.

Most of the new staff will be based in Hong Kong and will report to Raphael Blot, Hong Kong-based head of equity derivatives sales for Asia including Japan.

Patrick Ling started on the hedge fund sales team on December 1, moving over from UBS Singapore. He joins Shih-Loong Ngooil, who moved to the hedge fund sales team from UBS in August, and Guillaume Derville, who arrived from Macquarie Bank in July to head hedge fund sales for Asia.

In October, Kevin Lee joined as head of the Korea business from KBC Financial Products Hong Kong, and Sylvie Khau moved to the flow business from Commerzbank Singapore.

In September, Ilka Hsin joined the flow and distribution business from Merrill Lynch.

There were several new hires in August. Chiane Wong joined the Hong Kong warrants business from KBC, Vincent Kwan joined the flow and structured product business from Fortis, Melody Tsang joined the flow business from BNP Paribas, and Karen Lau moved to the flow and distribution business from Barclays Capital.

Also in August, Jim Wang arrived from Société Générale in Taipei to develop and maintain relationships with financial institutions in Taiwan and China. Remaining in Taiwan, he is the only one of Calyon's new hires to be based outside Hong Kong.

Two other Taiwan sales hires, both based in Hong Kong, are Darren Yen, who joined from BlackRock Merrill Lynch in October, and Sharon Lin, who arrived in June from Natixis.

Earlier this year, Calyon lost Dickson Cheung, formerly head of Asia equity derivatives marketing and sales, to Citi, and Nathan Larsen from the hedge fund sales team to Bear Stearns. Other departures included Justine Li and Delvin Tan from the private investor products team, who both joined ABN Amro.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here